Skip to main content
. Author manuscript; available in PMC: 2014 Jan 15.
Published in final edited form as: Toxicol Appl Pharmacol. 2012 Nov 9;266(2):233–244. doi: 10.1016/j.taap.2012.11.002

Figure 8. Vorinostat enhances cell polarity and reduces mesenchyme character.

Figure 8

(A) WB analysis for E-cadherin (*p=0.038), N-cadherin (*p=0.059) and fibronectin (p=0.074). (B) Image J analysis for EMT markers. (C) Immunofluorescence staining for EMT biomarkers in A431 cells following vorinostat treatment (2 μM) for 24 hrs (40 X magnifications).